FDA Label Decisions On Paxil Don't Deter Verdict Against GSK In Suicide Case
Chicago jury finds GSK failed to adequately warn about risk of suicidal behavior in patients over age 24 taking paroxetine; GSK argued that FDA had found no increased risk in this population.
You may also be interested in...
Drug makers are winning cases by getting expert testimony tossed, but the AndroGel verdict shows how narrow claims can benefit plaintiffs. The Pink Sheet offers a look at drugs in multidistrict litigation from Abilify to Zoloft.
Merck, AstraZeneca and Novo Nordisk's incretin mimetics win as district judge cites FDA’s history of rejecting pancreatic cancer warnings.
FDA proposed rule would allow ANDA holders to unilaterally make label changes prior to FDA’s approval; NDA and other ANDA holders would have 30 days to revise their labels once FDA approves the change.